Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such


COPENHAGEN, Denmark, November 11, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such.

1.Details of the person discharging managerial responsibilities/person closely associated  
a)NamePaul Chaplin
2.Reason for the notification
a)Position/status

 
President and Chief Executive Officer of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument


Identification code
Warrants


DK0015998017
b)Nature of the transactionGrant
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 0.00123,645
d)Aggregated information
  • Aggregated volume
  • Price
 

123,645
DKK 0.00
e)Date of the transaction2020-11-11
f)Place of the transactionOutside a trading venue


1.Details of the person discharging managerial responsibilities/person closely associated  
a)NameHenrik Juuel
2.Reason for the notification
a)Position/status

 
Executive Vice President and Chief Financial Officer of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument


Identification code
Warrants


DK0015998017
b)Nature of the transactionGrant
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 0.0056,210
d)Aggregated information
  • Aggregated volume
  • Price
 

56,210
DKK 0.00
e)Date of the transaction2020-11-11
f)Place of the transactionOutside a trading venue


1.Details of the person discharging managerial responsibilities/person closely associated  
a)NameHenrik Birk
2.Reason for the notification
a)Position/status

 
Executive Vice President and Chief Operating Officer of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument


Identification code
Warrants


DK0015998017
b)Nature of the transactionGrant
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 0.0052,617
d)Aggregated information
  • Aggregated volume
  • Price
 

52,617
DKK 0.00
e)Date of the transaction2020-11-11
f)Place of the transactionOutside a trading venue


1.Details of the person discharging managerial responsibilities/person closely associated  
a)NameTommi Kainu
2.Reason for the notification
a)Position/status

 
Executive Vice President and Chief Business Officer of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument


Identification code
Warrants


DK0015998017
b)Nature of the transactionGrant
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 0.0051,157
d)Aggregated information
  • Aggregated volume
  • Price
 

51,157
DKK 0.00
e)Date of the transaction2020-11-11
f)Place of the transactionOutside a trading venue


1.Details of the person discharging managerial responsibilities/person closely associated  
a)NameJean-Christophe May
2.Reason for the notification
a)Position/status

 
Executive Vice President and Chief Commercial Officer of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument


Identification code
Warrants


DK0015998017
b)Nature of the transactionGrant
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 0.0047,970
d)Aggregated information
  • Aggregated volume
  • Price
 

47,970
DKK 0.00
e)Date of the transaction2020-11-11
f)Place of the transactionOutside a trading venue


1.Details of the person discharging managerial responsibilities/person closely associated  
a)NameLaurence De Moerlooze
2.Reason for the notification
a)Position/status

 
Executive Vice President and Chief Medical Officer of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument


Identification code
Warrants


DK0015998017
b)Nature of the transactionGrant
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 0.0047,965
d)Aggregated information
  • Aggregated volume
  • Price
 

47,965
DKK 0.00
e)Date of the transaction2020-11-11
f)Place of the transactionOutside a trading venue


1.Details of the person discharging managerial responsibilities/person closely associated  
a)NameAnu Helena Kerns
2.Reason for the notification
a)Position/status

 
Executive Vice President People & Organization of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument


Identification code
Warrants


DK0015998017
b)Nature of the transactionGrant
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 0.0036,476
d)Aggregated information
  • Aggregated volume
  • Price
 

36,476
DKK 0.00
e)Date of the transaction2020-11-11
f)Place of the transactionOutside a trading venue

About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Strategic National Stockpile of a non-replicating smallpox vaccine, which has been approved by the FDA under the trade name JYNNEOS®, also for the protection against monkeypox. The vaccine is approved as a smallpox vaccine in Europe under the trade name IMVANEX® and in Canada under the trade name IMVAMUNE®. Our commercial product portfolio furthermore contains the market-leading vaccine Rabipur®/RabAvert® against rabies and Encepur® against tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, MVABEA®, which is licensed to Janssen. For more information visit www.bavarian-nordic.com.

Contacts
Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600

Company Announcement no. 48 / 2020

Attachment



Attachments

2020-48-en